Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
about
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.Development of a Multiplex PCR Test with Automated Genotyping Targeting E7 for Detection of Six High-Risk Human PapillomavirusesHigh Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature.A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequencyThe BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.Management of high-risk HPV-positive women for detection of cervical (pre)cancer.Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China.HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study.Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
P2860
Q35036033-110EA234-53F6-4A16-B0E8-995B2B99374CQ35667584-EF0F87FE-0999-42EB-98F2-5850253FE9B0Q36240353-44394052-0F45-4F8E-9C89-78FBF1CCB672Q36298250-21E1CC36-523A-4EB1-B45E-F02B73E7744DQ36783066-9B135C79-6FC0-4325-B9EB-B1CAA0E1E721Q37218627-2ED40FDC-87BA-408F-92D9-DE44C5AE7747Q38837737-4E66F3BF-3F5B-4615-9E64-3C34EBC6EE4DQ40906283-ABA6615D-EB12-4727-B06C-986DEA31F24BQ41736026-99CBAFCA-D854-4644-B1F0-CF29C74B6F1CQ47097439-804A1736-6D94-459D-AA8E-0F8C6D276578Q50095912-2DED7ED8-7C0C-47F8-ABF6-C7D4C6901E8CQ55365141-FD03FC4D-54A3-4967-B93E-CED3B97B31B3Q58703195-111E9952-CB04-456E-B507-C4461063C61DQ58748531-E05FE9EB-7C73-42B6-BF92-41E1177E6DDC
P2860
Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical validation of the HPV ...... NA by targeting the E7 region.
@en
Clinical validation of the HPV ...... NA by targeting the E7 region.
@nl
type
label
Clinical validation of the HPV ...... NA by targeting the E7 region.
@en
Clinical validation of the HPV ...... NA by targeting the E7 region.
@nl
prefLabel
Clinical validation of the HPV ...... NA by targeting the E7 region.
@en
Clinical validation of the HPV ...... NA by targeting the E7 region.
@nl
P2093
P2860
P356
P1476
Clinical validation of the HPV ...... NA by targeting the E7 region.
@en
P2093
A P van Splunter
A T Hesselink
D A M Heideman
F J van Kemenade
M G B Bleeker
M L van der Salm
T H Geelen
P2860
P304
P356
10.1128/JCM.03195-13
P407
P577
2014-01-03T00:00:00Z